Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. develops and commercializes therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure. Its principal medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Company news regularly covers Rezdiffra sales and patient adoption, quarterly financial results, regulatory and clinical development updates, and pipeline expansion through licensed assets such as ARO-PNPLA3, a clinical-stage siRNA program targeting PNPLA3, and an oral GLP-1 receptor agonist program. Madrigal also issues recurring corporate-governance updates, including Nasdaq inducement awards under its employee equity plans.
Madrigal (NASDAQ:MDGL) reported Phase 3 and real-world data showing Rezdiffra (resmetirom) reduced markers of cardiovascular and liver-related risk in patients with MASH.
According to Madrigal, Rezdiffra improved LDL-C, ApoB, Lp(a), liver stiffness, liver enzymes and ANTICIPATE-NASH risk scores, with favorable tolerability over follow-up periods up to two years.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on May 15, 2026 to 15 new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee pursuant to Nasdaq Listing Rule 5635(c)(4).
The employees received a total of 5,308 restricted stock units, vesting in four equal annual installments, subject to continued employment.
Madrigal (NASDAQ: MDGL) will present multiple new Rezdiffra® (resmetirom) data sets at the EASL Congress 2026, including analyses of lipid markers linked to cardiovascular risk, portal hypertension risk scores in compensated MASH cirrhosis, real-world effectiveness, and noninvasive biomarkers and machine learning models predicting MASH and fibrosis improvement.
Rezdiffra is the first approved MASH therapy in the U.S. and Europe, indicated for noncirrhotic MASH with F2–F3 fibrosis.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on May 1, 2026 to 47 new non‑executive employees under its 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Aggregated awards: 5,312 stock options, 17,589 time‑based RSUs and 1,839 performance RSUs.
Options use an exercise price of $513.72 (closing price on grant date). Time‑based awards vest over four years; options vest 25% after one year then 6.25% quarterly. Performance RSUs are earned on three‑year relative TSR versus a peer group and cliff vest in Q1 2029, subject to continued employment.
Madrigal Pharmaceuticals (Nasdaq: MDGL) reported 1Q26 Rezdiffra net sales of $311.3M, up 127% year-over-year, and >42,250 patients on therapy as of March 31, 2026. Cash and marketable securities totaled $817.9M. The company licensed ARO-PNPLA3 and added six preclinical siRNA programs; MGL-2086 Phase 1 is on track to start in 2Q26. First-quarter operating expenses were $404.1M with a net loss of $94.4M, which included $54.3M of one-time business development expenses. Intellectual property protection for Rezdiffra is expected into 2045.
Madrigal (NASDAQ: MDGL) licensed ARO-PNPLA3 from Arrowhead, adding a clinical-stage, GalNAc-conjugated siRNA targeting PNPLA3 to its MASH pipeline. Phase 1 data published in The New England Journal of Medicine showed up to 46% liver fat reduction in PNPLA3 I148M homozygous patients and a well-tolerated safety profile. Arrowhead will receive $25M upfront, up to $975M in milestones, plus royalties. Madrigal plans FDA consultation and Phase 2 combination studies with Rezdiffra.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) licensed ARO-PNPLA3 to Madrigal Pharmaceuticals in an exclusive global agreement announced May 5, 2026. Phase 1 data published in The New England Journal of Medicine showed up to 46% liver fat reduction in PNPLA3 I148M homozygous patients.
Financial terms: $25 million upfront, up to $975 million in milestones, and tiered royalties in the high-single digits to mid-teens.
Madrigal Pharmaceuticals (Nasdaq: MDGL) will release first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the U.S. market open. Management will host a live webcast at 8:00 a.m. Eastern Time to review financial and operating results, accessible via the company Investor Relations website.
The live webcast is recommended to be accessed by registering at least 15 minutes early and will be available on-demand about two hours after the live event.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on April 1, 2026 to 12 new non-executive employees under its 2025 Inducement Plan.
The company issued a total of 5,758 time-based restricted stock units, vesting in four equal annual installments beginning on the first anniversary, subject to continued employment and approved under Nasdaq Rule 5635(c)(4).
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on April 1, 2026 to 20 new non-executive employees under its 2025 Inducement Plan.
The independent Compensation Committee approved a total of 8,079 time-based restricted stock units that vest in four equal annual installments, subject to continued employment.